As of 2025-06-13, the Relative Valuation of Lineage Cell Therapeutics Inc (LCTX) is - USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.70 USD, the upside of Lineage Cell Therapeutics Inc based on Relative Valuation is -.
The range of the Relative Valuation is - USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | P/E |
| 2025-06-06 | -9.51 |
| 2025-06-05 | -9.26 |
| 2025-06-04 | -9.27 |
| 2025-06-03 | -9.55 |
| 2025-06-02 | -9.37 |
| 2025-05-30 | -9.37 |
| 2025-05-29 | -9.67 |
| 2025-05-28 | -9.19 |
| 2025-05-27 | -9.62 |
| 2025-05-23 | -9.85 |
| 2025-05-22 | -8.52 |
| 2025-05-21 | -7.20 |
| 2025-05-20 | -6.84 |
| 2025-05-19 | -7.01 |
| 2025-05-16 | -6.52 |
| 2025-05-15 | -6.63 |
| 2025-05-14 | -6.45 |
| 2025-05-13 | -6.62 |
| 2025-05-12 | -6.75 |
| 2025-05-09 | -6.20 |
| 2025-05-08 | -6.62 |
| 2025-05-07 | -6.26 |
| 2025-05-06 | -6.13 |
| 2025-05-05 | -6.46 |
| 2025-05-02 | -6.91 |
| 2025-05-01 | -7.10 |
| 2025-04-30 | -7.03 |
| 2025-04-29 | -6.64 |
| 2025-04-28 | -6.48 |
| 2025-04-25 | -6.90 |
| 2025-04-24 | -7.02 |
| 2025-04-23 | -6.65 |
| 2025-04-22 | -6.06 |
| 2025-04-21 | -5.64 |
| 2025-04-17 | -5.78 |
| 2025-04-16 | -5.87 |
| 2025-04-15 | -6.04 |
| 2025-04-14 | -6.26 |
| 2025-04-11 | -6.62 |
| 2025-04-10 | -5.78 |
| 2025-04-09 | -5.84 |
| 2025-04-08 | -5.44 |
| 2025-04-07 | -5.64 |
| 2025-04-04 | -6.09 |
| 2025-04-03 | -5.88 |
| 2025-04-02 | -6.16 |
| 2025-04-01 | -5.79 |
| 2025-03-31 | -6.36 |
| 2025-03-28 | -6.93 |
| 2025-03-27 | -7.00 |